Table III.
Multivariate Analysis of risk and treatment factors with development of CNS relapse (CNSR)
| Hazard Ratio | 95% CI | P | |
|---|---|---|---|
| Age | 0.99 | 0.95 - 1.03 | 0.72 |
| Gender (Male) | 1.10 | 0.40 – 3.00 | 0.85 |
| Enrolment Date | 0.50 | ||
| 1990-1995 | Reference | ||
| 1996-2010 | 0.48 | 0.06 - 4.11 | |
| CD4 count | 1.00 | 1.00 - 1.00 | 0.5 |
| Viral load | 1.00 | 1.00 - 1.00 | 0.09 |
| AIDS history | 1.40 | 0.45 - 4.39 | 0.56 |
| Concurrent cART Therapy | 1.90 | 0.23 15.97 | 0.56 |
| Histology | 0.07 | ||
| Diffuse large B-cell lymphoma | Reference | ||
| Burkitt/Burkitt-like lymphoma | 2.45 | 1.14 - 5.31 | |
| Other lymphomas | 1.25 | 0.15 - 10.59 | |
| Age-adjusted IPI | 0.77 | ||
| Low | Reference | ||
| Intermediate | 0.96 | 0.32 - 2.90 | |
| High | 0.61 | 0.12 - 3.03 | |
| CNSB | 3.68 | 1.49 – 9.10 | 0.005 |
| No | Reference | ||
| Yes | 3.67 | 1.49 - 9.10 | |
| Treatment1 | 0.71 | ||
| CHOP | Reference | ||
| Infusional1 | 0.00 | ||
| Dose intense1 | 1.15 | 0.47- 2.80 | |
| Less intense1 | 1.72 | 0.70 - 4.24 | |
| Rituximab | 0.26 | 0.05 - 1.42 | 0.12 |
| CR with initial treatment | 0.14 | 0.07 – 0.32 | <0.0001 |
All estimates in the multivariate analysis were adjusted for age, sex, time of enrolment (pre-cART era vs. cART era), CD4 count, viral load, prior history of AIDS, concurrent cART, histology, age-adjusted IPI, CNS involvement at baseline, type of initial chemotherapy, response to initial chemotherapy, and rituximab use.
AIDS, Acquired immunodeficiency syndrome; IPI, International Prognostic Index; cART, combination antiretroviral therapy; CNS, central nervous system; CR, complete response; 95%CI, 95% confidence interval; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone.
1
Chemotherapy regimens (see Table I for details)